The maker of Ozempic is facing stiff competition from rival obesity drug companies, as well as unproven knock-offs from China ...
Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Novo Nordisk's stock plummets over 13% after the company warns of potential sales and profit declines in 2026, facing increasing competition in the weight-loss market, particularly from Eli Lilly's ...
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...
Investor's Business Daily on MSN
Pfizer dives; why Lilly's Zepbound still looks like the weight-loss heavyweight
An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...
Novo Nordisk's stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...
Novo Nordisk has launched a pill version of its blockbuster weight-loss drug, Wegovy. Novo Nordisk's stock plunged Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results